In silico structure-based approaches to discover protein-protein interaction-targeting drugs.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Methods

• Publication date

  2017-12-01

• Fields of study

  Biology, Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.1016/j.ymeth.2017.08.006PMID 28802714PMCID PMC5683929
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modeling protein–protein and protein–peptide complexes: CAPRI 6th edition

  2017cited by this paper
• Modeling disordered protein interactions from biophysical principles

  2017cited by this paper
• Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.

  2017cited by this paper
• Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction.

  2017cited by this paper
• Combined Approach of Patch-Surfer and PL-PatchSurfer for Protein-Ligand Binding Prediction in CSAR 2013 and 2014

  2016cited by this paper
• Protein Engineering by Combined Computational and In Vitro Evolution Approaches.

  2016cited by this paper
• PL-PatchSurfer2: Improved Local Surface Matching-Based Virtual Screening Method That Is Tolerant to Target and Ligand Structure Variation

  2016cited by this paper
• DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites.

  2016cited by this paper
• Driving Structure-Based Drug Discovery through Cosolvent Molecular Dynamics.

  2016cited by this paper
• Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc

  2016cited by this paper
• A comprehensive map of molecular drug targets

  2016cited by this paper
• Three-Dimensional Compound Comparison Methods and Their Application in Drug Discovery

  2015cited by this paper
• Surfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI Inhibitors

  2015cited by this paper
• Identification of Potential Small Molecule Allosteric Modulator Sites on IL-1R1 Ectodomain Using Accelerated Conformational Sampling Method

  2015cited by this paper
• Selectivity by Small-Molecule Inhibitors of Protein Interactions Can Be Driven by Protein Surface Fluctuations

  2015cited by this paper
• The Contribution of Missense Mutations in Core and Rim Residues of Protein–Protein Interfaces to Human Disease

  2015cited by this paper
• Identification of Inhibitors of Biological Interactions Involving Intrinsically Disordered Proteins

  2015cited by this paper
• The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins

  2015cited by this paper
• iPPI-DB: an online database of modulators of protein–protein interactions

  2015cited by this paper
• Rational design of protein–protein interaction inhibitors

  2015cited by this paper
• DARC 2.0: Improved Docking and Virtual Screening at Protein Interaction Sites

  2015cited by this paper
• Small-molecule inhibitors of the Myc oncoprotein.

  2015cited by this paper
• A Designed Conformational Shift To Control Protein Binding Specificity**

  2014cited by this paper
• Which Three-Dimensional Characteristics Make Efficient Inhibitors of Protein-Protein Interactions?

  2014cited by this paper
• Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.

  2014cited by this paper
• Discovery of small molecule inhibitors targeting the SUMO–SIM interaction using a protein interface consensus approach

  2014cited by this paper
• Ligand Binding Mode Prediction by Docking: Mdm2/Mdmx Inhibitors as a Case Study

  2014cited by this paper
• Novel protein–protein interaction inhibitor of Nrf2–Keap1 discovered by structure-based virtual screening

  2014cited by this paper
• Fragment-based drug discovery and protein–protein interactions

  2014cited by this paper
• The new frontier of genome engineering with CRISPR-Cas9

  2014cited by this paper
• Efficient CRISPR/Cas9-Mediated Gene Editing in Arabidopsis thaliana and Inheritance of Modified Genes in the T2 and T3 Generations

  2014cited by this paper
• Rapid identification of Keap1-Nrf2 small-molecule inhibitors through structure-based virtual screening and hit-based substructure search.

  2014cited by this paper
• Modulators of protein-protein interactions.

  2014cited by this paper
• Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells

  2014cited by this paper
• Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model.

  2014cited by this paper
• Targeting protein-protein interaction by small molecules.

  2014cited by this paper
• Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.

  2014cited by this paper
• Small molecule modulators of protein-protein interactions: selected case studies.

  2014cited by this paper
• Targeting p53-MDM2-MDMX loop for cancer therapy.

  2014cited by this paper
• Targeting bromodomains: epigenetic readers of lysine acetylation

  2014cited by this paper
• Rational design of small-molecule inhibitors for β-catenin/T-cell factor protein-protein interactions by bioisostere replacement.

  2013cited by this paper
• Electrostatic Similarities between Protein and Small Molecule Ligands Facilitate the Design of Protein-Protein Interaction Inhibitors

  2013cited by this paper
• Expanding the Number of ‘Druggable’ Targets: Non‐Enzymes and Protein–Protein Interactions

  2013cited by this paper
• Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening

  2013cited by this paper
• 3did: a catalog of domain-based interactions of known three-dimensional structure

  2013cited by this paper
• Interactome3D: adding structural details to protein networks

  2013cited by this paper
• Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to p53-MDM2 Interaction Inhibitors

  2013cited by this paper
• Targeting protein-protein interactions as an anticancer strategy.

  2013cited by this paper
• Heritable genome editing in C. elegans via a CRISPR-Cas9 system

  2013cited by this paper
• TIMBAL v2: update of a database holding small molecules modulating protein–protein interactions

  2013cited by this paper
• EMDataBank unified data resource for 3DEM

  2013cited by this paper
• Computational design of protein-protein interactions.

  2013cited by this paper
• TALEN-based knockout library for human microRNAs

  2013cited by this paper
• DrugBank 4.0: shedding new light on drug metabolism

  2013cited by this paper
• Missing fragments: detecting cooperative binding in fragment-based drug design.

  2012cited by this paper
• SUMOylation in carcinogenesis.

  2012cited by this paper
• Diagnosing the decline in pharmaceutical R&D efficiency

  2012cited by this paper
• 2P2Idb: a structural database dedicated to orthosteric modulation of protein–protein interactions

  2012cited by this paper
• Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists

  2012cited by this paper
• Reverse engineering and analysis of large genome-scale gene networks

  2012cited by this paper
• Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2

  2012cited by this paper
• The distribution of ligand-binding pockets around protein-protein interfaces suggests a general mechanism for pocket formation

  2012cited by this paper
• Multi‐LZerD: Multiple protein docking for asymmetric complexes

  2012cited by this paper
• PocketQuery: protein–protein interaction inhibitor starting points from protein–protein interaction structure

  2012cited by this paper
• How Good Are State-of-the-Art Docking Tools in Predicting Ligand Binding Modes in Protein-Protein Interfaces?

  2012cited by this paper
• Chapter 4: Protein Interactions and Disease

  2012cited by this paper
• Relationship between Hot Spot Residues and Ligand Binding Hot Spots in Protein-Protein Interfaces

  2012cited by this paper
• Protein hot spots: the islands of stability.

  2012cited by this paper
• Analysis of Flexibility and Hotspots in Bcl-xL and Mcl-1 Proteins for the Design of Selective Small-Molecule Inhibitors.

  2012cited by this paper
• Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I).

  2011cited by this paper
• Structural conservation of druggable hot spots in protein–protein interfaces

  2011cited by this paper
• TALEs of genome targeting

  2011cited by this paper
• HotRegion: a database of predicted hot spot clusters

  2011cited by this paper
• Hydrophobic Binding Hot Spots of Bcl-xL Protein-Protein Interfaces by Cosolvent Molecular Dynamics Simulation.

  2011cited by this paper
• Why not consider a spherical protein? Implications of backbone hydrogen bonding for protein structure and function.

  2011cited by this paper
• A de novo protein binding pair by computational design and directed evolution.

  2011cited by this paper
• Further Evidence for the Likely Completeness of the Library of Solved Single Domain Protein Structures

  2011cited by this paper
• Multiple ligand simultaneous docking: Orchestrated dancing of ligands in binding sites of protein

  2010cited by this paper
• Structural space of protein–protein interfaces is degenerate, close to complete, and highly connected

  2010cited by this paper
• Evaluation of the performance of four molecular docking programs on a diverse set of protein‐ligand complexes

  2010cited by this paper
• Rationalizing the chemical space of protein-protein interaction inhibitors.

  2010cited by this paper
• Intrinsically disordered proteins are potential drug targets.

  2010cited by this paper
• Awakening guardian angels: drugging the p53 pathway

  2009cited by this paper
• AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

  2009cited by this paper
• Predicting druggable binding sites at the protein-protein interface.

  2009cited by this paper
• Protein-protein docking using region-based 3D Zernike descriptors

  2009cited by this paper
• Estimating the size of the human interactome

  2008cited by this paper
• A survey of available tools and web servers for analysis of protein-protein interactions and interfaces

  2008cited by this paper
• An empirical framework for binary interactome mapping

  2008cited by this paper
• Characterization of Protein–Protein Interfaces

  2008cited by this paper
• Protein–protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein

  2007cited by this paper
• Transient pockets on protein surfaces involved in protein-protein interaction.

  2007cited by this paper
• Hot spots—A review of the protein–protein interface determinant amino‐acid residues

  2007cited by this paper
• Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

  2007cited by this paper
• Comparison of shape-matching and docking as virtual screening tools.

  2007cited by this paper
• 3D Complex: A Structural Classification of Protein Complexes

  2006cited by this paper
• The impact of molecular biology on drug discovery.

  2006cited by this paper
• Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.

  2006cited by this paper
• Ligand efficiency indices as guideposts for drug discovery.

  2005cited by this paper
• Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites

  2005cited by this paper

• Integrative Protein Assembly With LZerD and Deep Learning in CAPRI 47-55.

  2025cites this paper
• Structure-based virtual screening and post-docking analysis of a D-amino acid oxidase inhibitor targeting the molecular surface.

  2025cites this paper
• Drug Delivery System for the Anticancer Drug Paclitaxel Using Lipocalin-Type Prostaglandin D Synthase Conjugated to a Tumor-Targeting Peptide

  2025cites this paper
• MnM-W-MMGBSA: A Computational Strategy to Improve Relative Binding Free Energies of Protein–Protein Interaction Systems

  2025cites this paper
• Alphappimi: a comprehensive deep learning framework for predicting PPI-modulator interactions

  2025cites this paper
• Insights into Binding Mechanisms of Potential Inhibitors Targeting PCSK9 Protein via Molecular Dynamics Simulation and Free Energy Calculation

  2025cites this paper
• Molecular Insights into the Oil Palm (Elaeis guineensis) Defense Response to Ganoderma boninense Infection

  2025cites this paper
• In Silico Identification of Potential Antagonists Targeting the HPV16 E2-E1 Interaction: A Step Toward Novel Therapeutics for Cervical Cancer

  2025cites this paper
• Identification of Compounds Against Anti‐apoptotic Bcl‐2 Protein Using Docking Studies

  2024cites this paper
• New insights into protein–protein interaction modulators in drug discovery and therapeutic advance

  2024cites this paper
• Single-Molecule-Based, Label-Free Monitoring of Molecular Glue Efficacies for Promoting Protein–Protein Interactions Using YaxAB Nanopores

  2024cites this paper
• Arginine (315) is required for the PLIN2-CGI-58 interface and plays a functional role in regulating nascent LDs formation in bovine adipocytes.

  2024cites this paper
• Interface-aware molecular generative framework for protein–protein interaction modulators

  2024cites this paper
• İLAÇ TASARIMINDA YAPAY ZEKÂ UYGULAMALARI

  2023cites this paper
• DLiP-PPI library: An integrated chemical database of small-to-medium-sized molecules targeting protein–protein interactions

  2023cites this paper
• A Way for Finding Ligands for New Binding Sites

  2023cites this paper
• Evaluating protein binding interfaces with transformer networks

  2023cites this paper
• Generating Potential Protein-Protein Interaction Inhibitor Molecules Based on Physicochemical Properties

  2023cites this paper
• Mycobacterium tuberculosis – Macrophage Interactome: Molecular Network Structure and Resilience against Antibiotics

  2023cites this paper
• Deep learning-assisted prediction of protein-protein interactions in Arabidopsis thaliana.

  2023cites this paper
• Pathogen-driven cancers from a structural perspective: Targeting host-pathogen protein-protein interactions

  2023cites this paper
• Quantitative comparison of protein-protein interaction interface using physicochemical feature-based descriptors of surface patches

  2023cites this paper
• Rational approaches to discover SARS-CoV-2/ACE2 interaction inhibitors: Pharmacophore-based virtual screening, molecular docking, molecular dynamics and binding free energy studies

  2023cites this paper
• A Computational Approach to Identify Small Molecules Interact with Crystal Structure of Programmed Cell Death Protein 1 as Potential Therapeutics for Cancer Immunotherapy

  2023cites this paper
• Solvatochromic peptidic binder obtained via extended phage display acts as a fluororeporter for fragment-based drug discovery (FBDD)

  2022cites this paper
• Druggable sites/pockets of the p53-DNAJA1 protein-protein interaction: In silico modeling and in vitro/in vivo validation.

  2022cites this paper
• Interface inhibitory action on Interleukin-1β using selected anti-inflammatory compounds to mitigate the depression: A computational investigation

  2022cites this paper
• Solubility-Aware Protein Binding Peptide Design Using AlphaFold

  2022cites this paper
• Structural and evolutionary exploration of the IL-3 family and its alpha subunit receptors

  2021cites this paper
• Exploring Molecular Contacts of MUC1 at CIN85 Binding Interface to Address Future Drug Design Efforts

  2021cites this paper
• Identification of novel inhibitors of Keap1/Nrf2 by a promising method combining protein–protein interaction-oriented library and machine learning

  2021cites this paper
• Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor

  2021cites this paper
• Targeting SARS‐CoV‐2 Spike Protein/ACE2 Protein‐Protein Interactions: a Computational Study

  2021cites this paper
• Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

  2021cites this paper
• Docking, Scoring, and Virtual Screening in Drug Discovery

  2021cites this paper
• A novel approach for studying receptor-ligand interactions on living cells surface by using NUS/T1ρ-NMR methodologies combined with computational techniques: The RGDechi15D-αvβ5 integrin complex

  2021cites this paper
• Rational approaches to discover SARS-CoV-2/ACE2 interaction inhibitors: from pharmacophore-based virtual screening to molecular dynamics

  2021cites this paper
• Machine Learning in Drug Discovery: A Review

  2021cites this paper
• Hot Spot Analysis of YAP-TEAD Protein-Protein Interaction Using the Fragment Molecular Orbital Method and Its Application for Inhibitor Discovery

  2021cites this paper
• Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction

  2021cites this paper
• Analysis of physicochemical properties of protein-protein interaction modulators suggests stronger alignment with the "rule of five".

  2021cites this paper
• Molecular Imaging of Protein–Protein Interactions and Protein Folding

  2021cites this paper
• Allosteric binding on nuclear receptors: Insights on screening of non-competitive endocrine-disrupting chemicals.

  2021cites this paper
• A strategy for designing allosteric modulators of transcription factor dimerization

  2020cites this paper
• Path-LZerD: Predicting Assembly Order of Multimeric Protein Complexes

  2020cites this paper
• Analyzing In Silico the Relationship Between the Activation of the Edema Factor and Its Interaction With Calmodulin

  2020cites this paper
• Computational design of small molecular modulators of protein–protein interactions with a novel thermodynamic cycle: Allosteric inhibitors of HIV‐1 integrase

  2020cites this paper
• Current Challenges and Opportunities in Designing Protein–Protein Interaction Targeted Drugs

  2020cites this paper
• Computational Approaches for Drug Target Identification

  2020cites this paper
• A novel method for analysis of the electrostatic complementarity of protein-protein interaction based on fragment molecular orbital method

  2020cites this paper
• Protein – Protein Etkileşimi Tespit Yöntemleri, Veri Tabanları ve Veri Güvenilirliği

  2020cites this paper
• In silico identification of small molecule modulators for disruption of Hsp90–Cdc37 protein–protein interaction interface for cancer therapeutic application

  2020cites this paper
• Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting its Protein-Protein Interactions

  2020cites this paper
• Peptide-based Inhibitors of Protein-Protein Interactions of Src Homology 2 Domain-Containing Phosphatase 2

  2020cites this paper
• Rapid in silico Design of Potential Cyclic Peptide Binders Targeting Protein-Protein Interfaces

  2020cites this paper
• The Molecular Basis of JAZ-MYC Coupling, a Protein-Protein Interface Essential for Plant Response to Stressors

  2020cites this paper
• An Improved Genetic with Particle Swarm Optimization Algorithm Based on Ensemble Classification to Predict Protein–Protein Interaction

  2020cites this paper
• Mechanisms Inspired Targeting Peptides.

  2020cites this paper
• Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy

  2020cites this paper
• Protein-Protein Interactions: An Overview

  2019cites this paper
• Probing the Druggablility on the Interface of the Protein–Protein Interaction and Its Allosteric Regulation Mechanism on the Drug Screening for the CXCR4 Homodimer

  2019cites this paper
• Artificial intelligence facilitates drug design in the big data era

  2019cites this paper
• Chimeric protein-protein interface inhibitors allow efficient inhibition of Type III secretion machinery and Pseudomonas aeruginosa virulence.

  2019cites this paper
• Computational identification of protein-protein interactions in model plant proteomes

  2019cites this paper
• AngularQA: Protein Model Quality Assessment with LSTM Networks

  2019cites this paper
• A Complete Assessment of Dopamine Receptor- Ligand Interactions through Computational Methods

  2019cites this paper
• Methods for Discovering and Targeting Druggable Protein-Protein Interfaces and Their Application to Repurposing.

  2018cites this paper
• Targeting Focal Adhesion Kinase Using Inhibitors of Protein-Protein Interactions

  2018cites this paper
• Protein Structure Prediction Using Coarse-Grained Models

  2018cites this paper
• Artificial intelligence in drug design

  2018cites this paper
• Hot-spot analysis for drug discovery targeting protein-protein interactions

  2018influential citation
• Modeling the assembly order of multimeric heteroprotein complexes

  2018cites this paper
• WarpEngine, a Flexible Platform for Distributed Computing Implemented in the VEGA Program and Specially Targeted for Virtual Screening Studies

  2018cites this paper
• Systems approaches for identifying disease genes and drug targets.

  2017cites this paper
• Recent Deep Learning Applications to Structure-Based Drug Design.

  year unknowncites this paper
• Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development

  year unknowncites this paper